50-12-102. Definitions. As used in this part, the following definitions apply: 
 (1) "Eligible patient" means an individual who meets the requirements of 50-12-104. 
 (2) "Health care facility" has the meaning provided in 50-5-101. 
 (3) "Health care provider" means any of the following individuals licensed pursuant to Title 37: 
 (a) a physician; 
 (b) an advanced practice registered nurse authorized by the board of nursing to prescribe medicine; and 
 (c) a physician assistant whose duties and delegation agreement allows the physician assistant to undertake the activities allowed under this part. 
 (4) "Investigational drug, biological product, or device" means a drug, biological product, or device that: 
 (a) has successfully completed phase 1 of a clinical trial but has not yet been approved for general use by the United States food and drug administration; and 
 (b) remains under investigation in a United States food and drug administration-approved clinical trial. 
 (5) "Terminal illness" means a progressive disease or medical or surgical condition that: 
 (a) entails significant functional impairment; 
 (b) is not considered by a treating health care provider to be reversible even with administration of a treatment currently approved by the United States food and drug administration; and 
 (c) without life-sustaining procedures, will result in death. 
 (6) "Written informed consent" means a written document that meets the requirements of 50-12-105. 
 History: En. Sec. 2, Ch. 135, L. 2015.
Structure Montana Code Annotated
Chapter 12. Treatments for Chronic or Terminal Illness
50-12-103. Availability of experimental drugs
50-12-104. Eligible patient -- requirements
50-12-105. Written informed consent required
50-12-106. Effect on insurance coverage and health care services
50-12-107. Heirs not liable for payments
50-12-108. Disciplinary action prohibited